New Rules Proposed for How the UK Licenses Medical Devices and Shares Safety Data

What happened

On 1 September 2026 the government tabled three amendments to its Health Bill. All three are about how the MHRA, the UK's medicines and medical devices regulator, is allowed to work. The first is about information sharing. It would let the MHRA share certain information about medicines and medical devices with trusted UK government bodies and with regulators in other countries, where that supports public health and patient safety. Existing protections for commercially sensitive information and for patient data would stay in place. The second is about keeping rules up to date. At the moment, when an international technical standard changes, UK law can lag behind. The amendment would let legislation automatically reflect updates to technical standards and international guidelines, and would allow the amount of consultation to be matched to how significant a change actually is. The third is the most substantial. It would create enabling powers for a future licensing system for medical devices. Under that model, devices placed on the Great Britain market could need a licence from the MHRA itself, rather than relying on assessment by a third-party organisation. One important detail: none of this changes anything today. The published proposals contain no immediate changes to how medicines or medical devices are regulated.

Why this matters

"Medical device" sounds like it means hospital scanners. It is far broader than that. It covers blood pressure monitors, blood glucose meters, inhaler spacers, hearing aids, insulin pumps, hip replacements, pregnancy tests and a growing amount of software. That last category is the reason this is happening now. Software that helps read a scan, flag a suspicious result or triage a patient can count as a medical device. Increasingly some of that software uses artificial intelligence. AI-enabled devices create a problem that older rules were never designed for. A metal hip behaves the same way in ten years as it does today. A piece of software can be updated repeatedly, and a system that learns can shift its behaviour over time. Regulating something that changes after it has been approved is genuinely difficult. There is also the memory of past device failures. The UK has been through serious problems with implants and devices where issues took far too long to be spotted and acted on. Better information sharing between regulators is a direct response to that kind of history. So the underlying question is a fair one: can a regulator keep up with technology that moves faster than the law does?

What the evidence actually says

It is worth being careful about what has actually happened here, because "new rules proposed" is not the same as "new rules in force". What exists today is a set of amendments tabled to a Bill. They are enabling powers. That means they would give ministers and the regulator the ability to build a system later, not the system itself. The published material is explicit that any future licensing regime would need further development, consultation and parliamentary scrutiny before it could take effect. In the meantime, the existing UKCA marking regime stays in place, and Northern Ireland continues to apply EU rules under the Windsor Framework. There are reasonable arguments on both sides, and it would be dishonest to present only one. In favour: direct licensing could give the regulator a clearer view of what is on the market and strengthen its capacity and resilience. Faster alignment with international standards could reduce the gap between what is technically best practice and what UK law requires. Better data sharing between regulators could catch problems earlier. Against, or at least worth watching: a licensing system concentrates work in the regulator, and that only helps if the regulator is properly resourced. Rules that update automatically are efficient, but they reduce the amount of scrutiny each individual change receives. How consultation is scaled to significance will matter a great deal in practice. None of that is settled yet, which is precisely why it is being debated in Parliament.

Qurexa perspective

Qurexa works in healthcare logistics and pharmacy delivery, so device regulation is part of the background we operate in rather than something abstract. A lot of what people use at home is regulated as a medical device. Blood glucose meters, blood pressure monitors, inhaler spacers, compression stockings, dressings. When patients ask us about these, the questions are almost always practical: is this one any good, and how do I know? One genuinely useful habit, whatever happens with this Bill: if you buy a health device yourself rather than getting it through the NHS, buy it from a reputable UK supplier and keep the paperwork. Cheap unbranded monitors sold through overseas marketplaces are a recurring problem, because a blood pressure reading that is quietly wrong is worse than no reading at all. The other habit is reporting. If a device you use fails, behaves oddly or causes harm, that can be reported through the MHRA's Yellow Card scheme. Most people have heard of Yellow Card for medicine side effects and do not realise it covers devices too. Safety systems only work when people actually tell them things.

Practical advice

Nothing changes for patients right now, so there is no action you need to take today. But there are sensible things to do anyway. If you use a medical device at home, check that you know how to use it correctly. Blood pressure monitors in particular give misleading readings if the cuff is the wrong size, on the wrong part of the arm, or used straight after rushing about. Your pharmacist can check your technique in a couple of minutes. If you are buying a device yourself, look for a proper UK conformity marking, buy from a supplier you can contact if something goes wrong, and be sceptical of anything that promises to diagnose a condition on its own. If a device fails or seems to harm someone, report it to the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk. You do not need to be certain the device caused the problem to report it. If you use a health app that gives you medical advice or readings, treat its output as information to discuss, not a verdict. That applies particularly to anything using AI. And if you want to follow this Bill, gov.uk and the MHRA publish updates. Public consultations on any future licensing regime would be open to responses, including from patients.

What to know

On 1 September 2026 the government tabled three MHRA-related amendments to its Health Bill: wider information sharing with trusted UK and international partners, faster alignment with updated technical standards, and enabling powers for a possible future licensing regime for medical devices in Great Britain. The key thing to hold on to is that nothing has changed yet. These are enabling powers, and any real licensing system would need further development, consultation and parliamentary scrutiny. UKCA marking continues for now, and Northern Ireland still follows EU rules under the Windsor Framework. The reason it is worth caring about is AI. Software that learns and updates does not fit neatly into rules written for physical objects, and regulators everywhere are working out what to do about it. In the meantime, the useful personal steps are unchanged: use home devices properly, buy from reputable suppliers, and report problems through Yellow Card. Sources: Department of Health and Social Care and MHRA, "MHRA regulatory reform amendments tabled in Government's Health Bill", 1 September 2026, https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill | Medicines and Healthcare products Regulatory Agency, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency | MHRA Yellow Card scheme, https://yellowcard.mhra.gov.uk/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. If you have concerns about a medical device you are using, speak to your pharmacist, GP practice or the clinician who supplied it.